These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Current treatment of chronic beryllium disease. Sood A J Occup Environ Hyg; 2009 Dec; 6(12):762-5. PubMed ID: 19894178 [TBL] [Abstract][Full Text] [Related]
7. Justification for screening for chronic beryllium disease: closer to reality. Rossman MD Eur Respir J; 2008 Sep; 32(3):543-4. PubMed ID: 18757694 [No Abstract] [Full Text] [Related]
8. TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization. Sato H; Silveira L; Fingerlin T; Dockstader K; Gillespie M; Lagan AL; Lympany P; Sawyer RT; du Bois RM; Welsh KI; Maier LA J Allergy Clin Immunol; 2007 Mar; 119(3):687-96. PubMed ID: 17208287 [TBL] [Abstract][Full Text] [Related]
9. Beryllium induces IL-2 and IFN-gamma in berylliosis. Tinkle SS; Kittle LA; Schumacher BA; Newman LS J Immunol; 1997 Jan; 158(1):518-26. PubMed ID: 8977230 [TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290 [TBL] [Abstract][Full Text] [Related]
11. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Newman LS; Kreiss K; King TE; Seay S; Campbell PA Am Rev Respir Dis; 1989 Jun; 139(6):1479-86. PubMed ID: 2729754 [TBL] [Abstract][Full Text] [Related]
12. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. Tinkle SS; Kittle LA; Newman LS J Immunol; 1999 Sep; 163(5):2747-53. PubMed ID: 10453017 [TBL] [Abstract][Full Text] [Related]
13. Recent chronic beryllium disease in residents surrounding a beryllium facility. Maier LA; Martyny JW; Liang J; Rossman MD Am J Respir Crit Care Med; 2008 May; 177(9):1012-7. PubMed ID: 18244954 [TBL] [Abstract][Full Text] [Related]
14. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP. Sawyer RT; Parsons CE; Fontenot AP; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Newman LS Am J Respir Cell Mol Biol; 2004 Jul; 31(1):122-30. PubMed ID: 14975942 [TBL] [Abstract][Full Text] [Related]
15. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Newman LS; Mroz MM; Balkissoon R; Maier LA Am J Respir Crit Care Med; 2005 Jan; 171(1):54-60. PubMed ID: 15374840 [TBL] [Abstract][Full Text] [Related]
16. 5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects. Day BJ; Huang J; Barkes BQ; Gillespie M; Li L; Maier LA Lung; 2018 Feb; 196(1):103-114. PubMed ID: 29080069 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Inoue Y; Barker E; Daniloff E; Kohno N; Hiwada K; Newman LS Am J Respir Crit Care Med; 1997 Jul; 156(1):109-15. PubMed ID: 9230733 [TBL] [Abstract][Full Text] [Related]
19. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. McCanlies EC; Ensey JS; Schuler CR; Kreiss K; Weston A Am J Ind Med; 2004 Aug; 46(2):95-103. PubMed ID: 15273960 [TBL] [Abstract][Full Text] [Related]
20. A canine model of beryllium-induced granulomatous lung disease. Haley PJ; Finch GL; Mewhinney JA; Harmsen AG; Hahn FF; Hoover MD; Muggenburg BA; Bice DE Lab Invest; 1989 Aug; 61(2):219-27. PubMed ID: 2755079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]